Biologic Drugs With Established Pharmaceutical Class: CD20-directed Cytolytic Antibody
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: CD20-directed Cytolytic Antibody
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 1997-11-26 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 2009-10-26 | ⤷ Get Started Free | ⤷ Get Started Free |
| Genentech, Inc. | GAZYVA | obinutuzumab | Injection | 125486 | 2013-11-01 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
